Onco-Summaries: Daily Oncology Updates at a Glance

27/05/2026

---

• FDA grants Fast Track to Solu’s STX‑0712 for relapsed/refractory CMML, advancing CyTAC™ platform into Phase 1 hematology trials

---

FDA grants Fast Track to Solu’s STX‑0712 for relapsed/refractory CMML, advancing CyTAC™ platform into Phase 1 hematology trials (Ref)

Solu Therapeutics’ investigational therapy STX-0712 has received Fast Track designation for relapsed/refractory chronic myelomonocytic leukemia (CMML)

Ongoing Trials - A Phase 1, open-label, multicenter trial is ongoing in CMML and AML patients

• Initial data expected to be presented at a hematology conference later this year

Return to Top